MedTrace Logo

Cetuximab Plus Biweekly Capecitabine and Oxaliplatin in KRAS Wild Type Metastatic Colorectal Cancer

NCT00444678 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2020-04-03

Study results available
· View outcomes & findings →

Summary

This is a Phase II, open label, non-randomized study in subjects with histologically confirmed diagnosis of advanced KRAS wild type adenocarcinoma of the colon or rectum, who have not received prior chemotherapy for metastatic disease.

Conditions

Interventions

DRUG

Cetuximab

500 mg/m2, IV every two weeks

DRUG

Oxaliplatin

85 mg/m2, IV, q 2 weeks

DRUG

Capecitabine

2500 mg, po bid x 7 days every two weeks

Sponsors & Collaborators

Principal Investigators

  • Deirdre Cohen, MD · NYU Langone Health

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-06-01
Primary Completion
2012-08-01
Completion
2015-06-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00444678 on ClinicalTrials.gov